| Year |
Citation |
Score |
| 2023 |
Tyagi A, Jaggupilli A, Ly S, Yuan B, El-Dana F, Hegde VL, Anand V, Kumar B, Puppala M, Yin Z, Wong STC, Mollard A, Vankayalapati H, Foulks JM, Warner SL, et al. TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax. Leukemia. PMID 38007585 DOI: 10.1038/s41375-023-02086-6 |
0.392 |
|
| 2023 |
Sakemura RL, Hefazi M, Cox MJ, Siegler EL, Sinha S, Hansen MJ, Stewart CM, Feigin JM, Manriquez Roman C, Schick KJ, Can I, Tapper EE, Horvei P, Adada MM, Bezerra ED, ... ... Warner SL, et al. AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells. Cancer Immunology Research. PMID 37378662 DOI: 10.1158/2326-6066.CIR-22-0254 |
0.745 |
|
| 2021 |
Zhang Y, Arner EN, Rizvi A, Toombs JE, Huang H, Warner SL, Foulks JM, Brekken RA. AXL inhibitor TP-0903 reduces metastasis and therapy resistance in pancreatic cancer. Molecular Cancer Therapeutics. PMID 34675118 DOI: 10.1158/1535-7163.MCT-21-0293 |
0.326 |
|
| 2021 |
Chan TY, Egbert CM, Maxson JE, Siddiqui A, Larsen LJ, Kohler K, Balasooriya ER, Pennington KL, Tsang TM, Frey M, Soderblom EJ, Geng H, Müschen M, Forostyan TV, Free S, ... ... Warner SL, et al. TNK1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth. Nature Communications. 12: 5337. PMID 34504101 DOI: 10.1038/s41467-021-25622-3 |
0.415 |
|
| 2020 |
Taverna JA, Hung CN, DeArmond DT, Chen M, Lin CL, Osmulski PA, Gaczynska ME, Wang CM, Lucio ND, Chou CW, Chen CL, Nazarullah A, Lampkin SR, Qiu L, Bearss DJ, ... Warner S, et al. Single-cell Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer. Cancer Research. PMID 31992541 DOI: 10.1158/0008-5472.Can-19-3183 |
0.454 |
|
| 2020 |
Garrido-Laguna I, Dillon PM, Anthony SP, Janat-Amsbury M, Ashenbramer N, Warner SL, Mouritsen L, Wade ML, Whatcott C, Bearss D, Fu S. A phase I, first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-3654 administered daily for 28 days to patients with advanced solid tumors. Journal of Clinical Oncology. 38: 3586-3586. DOI: 10.1200/Jco.2020.38.15_Suppl.3586 |
0.41 |
|
| 2020 |
Jeon JY, Eisenmann E, Niu M, Garrison D, Buelow D, Thomas MZ, Whatcott C, Warner S, Orwick S, Hertlein E, Byrd J, Bhatnagar B, Baker SD. Activity of the multikinase inhibitor TP‐0903 in RAS mutant acute myeloid leukemia The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.02655 |
0.323 |
|
| 2019 |
Sinha S, Secreto CR, Boysen JC, Warner SL, Bearss DJ, Ghosh AK, Kay NE. Β-Catenin and Axl Receptor Tyrosine Kinase Modulation in CLL B-Cells with Co-Culture on Marrow Stromal Cells: Implications for Drug Resistance Blood. 134: 1739-1739. DOI: 10.1182/Blood-2019-121772 |
0.407 |
|
| 2019 |
Kumagai Y, Oishi J, Nakamura M, Foulks JM, Whatcott CJ, Warner SL, Bearss DJ, Goto M. Abstract 3969: TP-0903, a potent AXL receptor tyrosine kinase inhibitor, enhances the activity of anti-PD-1 therapy in a metastatic preclinical syngeneic model of breast cancer Cancer Research. 79: 3969-3969. DOI: 10.1158/1538-7445.Sabcs18-3969 |
0.464 |
|
| 2019 |
Mangelson R, Tyagi E, Peterson P, Siddiqui-Jain A, Whatcott CJ, Bearss DJ, Warner SL. Abstract 3804: The potent AXL kinase inhibitor, TP-0903, is active in pre-clinical models of EGFR positive non-small cell lung cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-3804 |
0.456 |
|
| 2019 |
Wade ML, Mouritsen CL, Matsumura Y, Bryan BV, Bearss DJ, Warner SL. Abstract 3166: Evaluation of genetic modulation ofACVR1(akaALK2) kinase gene as a clinical biomarker of the ACVR1 inhibitor TP-0184 Cancer Research. 79: 3166-3166. DOI: 10.1158/1538-7445.Am2019-3166 |
0.35 |
|
| 2019 |
Mangelson R, Peterson P, Foulks JM, Matsumura Y, Mouritsen L, Whatcott CJ, Bearss DJ, Warner SL. Abstract 2197: The AXL kinase inhibitor, TP-0903, demonstrates efficacy in preclinical models of colorectal cancer independent of KRAS mutation status Cancer Research. 79: 2197-2197. DOI: 10.1158/1538-7445.Am2019-2197 |
0.489 |
|
| 2019 |
Tomimatsu N, Fujimura K, Matsumura Y, Umehara H, Mouritsen L, Warner SL, Bearss DJ. Abstract 2006: Targeting AXL kinase with TP-0903 successfully reverses the mesenchymal phenotype and extends survival in preclinical models of advanced ovarian cancer Cancer Research. 79: 2006-2006. DOI: 10.1158/1538-7445.Am2019-2006 |
0.496 |
|
| 2019 |
Zhang Y, Arner EN, Toombs JE, Foulks JM, Warner SL, Brekken RA. Abstract C092: Axl inhibitor TP-0903 augments chemo- and immunotherapy efficacy in pancreatic cancer Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-C092 |
0.441 |
|
| 2019 |
Forostyan TV, Weagel E, Matsumura Y, Tyagi E, Foulks JM, Whatcott CJ, Siddiqui-Jain A, Bearss DJ, Warner SL. Abstract C081: Targeting CDK9 and MCL1 in castration-sensitive and resistant prostate cancer models Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-C081 |
0.438 |
|
| 2019 |
Pathi S, Peterson P, Mangelson R, Tyagi E, Foulks JM, Whatcott CJ, Bearss DJ, Warner SL. Abstract B080: PKM2 activation modulates metabolism and enhances immune response in solid tumor models Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-B080 |
0.464 |
|
| 2018 |
Sinha S, Boysen JC, Chaffee KG, Kabat BF, Slager SL, Parikh SA, Secreto CR, Call T, Shanafelt TD, Leis JF, Warner SL, Bearss DJ, Ghosh AK, Kay NE. Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy. Oncotarget. 9: 37173-37184. PMID 30647852 DOI: 10.18632/Oncotarget.26444 |
0.496 |
|
| 2018 |
Sarantopoulos J, Beg MS, Fotopoulos G, Taverna JA, Anthony SP, Weitman SD, Warner SL, Mouritsen L, Bearss D, Smith S, Beever H, Khemka V. A phase 1a / 1b first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-0903, a potent inhibitor of AXL kinase, administered daily for 21 days to patients with advanced solid tumors. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.Tps2612 |
0.454 |
|
| 2018 |
Tyagi E, Whatcott C, Foulks JM, Siddiqui-Jain A, Bearss DJ, Warner SL. The Oral CDK9 Inhibitor, TP-1287, Is Active in Non-Clinical Models of Multiple Myeloma Blood. 132: 3269-3269. DOI: 10.1182/Blood-2018-99-120047 |
0.499 |
|
| 2018 |
Kim W, Whatcott C, Siddiqui-Jain A, Anthony S, Bearss DJ, Warner SL. The CDK9 Inhibitor, Alvocidib, Potentiates the Non-Clinical Activity of Azacytidine or Decitabine in an MCL-1-Dependent Fashion, Supporting Clinical Exploration of a Decitabine and Alvocidib Combination Blood. 132: 4355-4355. DOI: 10.1182/Blood-2018-99-119793 |
0.458 |
|
| 2018 |
Nath D, Dutta A, Yang Y, Whatcott C, Warner SL, Mohi G. The PIM Kinase Inhibitor TP-3654 in Combination with Ruxolitinib Exhibits Marked Improvement of Myelofibrosis in Murine Models Blood. 132: 54-54. DOI: 10.1182/Blood-2018-99-119421 |
0.441 |
|
| 2018 |
Sakemura R, Yang N, Cox MJ, Sinha S, Hefazi M, Hansen MJ, Schick KJ, Forsman CL, Boysen JC, Tschumper RC, Juarez Diaz E, Mouritsen L, Foulks JM, Warner SL, Parikh SA, et al. Axl-RTK Inhibition Modulates T Cell Functions and Synergizes with Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies Blood. 132: 728-728. DOI: 10.1182/Blood-2018-99-112209 |
0.467 |
|
| 2018 |
Sinha S, Secreto CR, Boysen JC, Warner SL, Bearss DJ, Ghosh AK, Kay NE. Enhanced Expression of Beta-Catenin and Axl Receptor Tyrosine Kinase (RTK) in Chronic Lymphocytic Leukemia (CLL) B-Cells with Co-Culture on Marrow Stromal Cells: Implications for Leukemic Cell Drug Resistance Blood. 132: 3125-3125. DOI: 10.1182/Blood-2018-99-110981 |
0.417 |
|
| 2018 |
Sinha S, Secreto C, Boysen J, Warner SL, Bearss DJ, Ghosh A, Kay NE. Abstract 2144: Enhanced expression of β-catenin and Axl receptor tyrosine kinase in chronic lymphocytic leukemia (CLL) B-cells with co-culture on marrow stromal cells: Implications for drug resistance Cancer Research. 78: 2144-2144. DOI: 10.1158/1538-7445.Am2018-2144 |
0.405 |
|
| 2018 |
Haws H, Kim W, Siddiqui-Jain A, Bearss DJ, Warner SL, Whatcott CJ. Abstract B178: Targeting Myc in triple-negative breast cancer models through the dual inhibition of PIM kinases and CDK9 Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-B178 |
0.524 |
|
| 2018 |
Peterson P, Whatcott CJ, Bearss DJ, Warner SL, Siddiqui-Jain A. Abstract B024: PKM2 activation suppresses cellular ROS scavenging capacity and potentiates doxorubicin antitumor activity Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-B024 |
0.507 |
|
| 2017 |
Bogenberger J, Whatcott C, Hansen N, Delman D, Shi CX, Kim W, Haws H, Soh K, Lee YS, Peterson P, Siddiqui-Jain A, Weitman S, Stewart K, Bearss D, Mesa R, ... Warner S, et al. Combined venetoclax and alvocidib in acute myeloid leukemia. Oncotarget. 8: 107206-107222. PMID 29291023 DOI: 10.18632/Oncotarget.22284 |
0.435 |
|
| 2017 |
Chen T, Sorna V, Choi S, Call L, Bearss J, Carpenter K, Warner SL, Sharma S, Bearss DJ, Vankayalapati H. Fragment-based design, synthesis, biological evaluation, and SAR of 1H-benzo[d]imidazol-2-yl)-1H-indazol derivatives as potent PDK1 inhibitors. Bioorganic & Medicinal Chemistry Letters. PMID 29150397 DOI: 10.1016/J.Bmcl.2017.10.041 |
0.458 |
|
| 2017 |
Peterson P, Whatcott C, Siddiqui-Jain A, Weitman S, Kieran M, Bearss DJ, Warner SL. TP-0184 Inhibits ALK2/ACVR1, Decreases Hepcidin Levels, and Demonstrates Activity in Preclinical Mouse Models of Functional Iron Deficiency Blood. 130: 937-937. DOI: 10.1182/Blood.V130.Suppl_1.937.937 |
0.392 |
|
| 2017 |
Jeon JY, Park I, Buelow DR, Whatcott C, Warner SL, Blum W, Baker S. TP-0903, a Novel Axl Inhibitor with Activity in Drug Resistant FLT3-ITD+ AML through a Mechanism That Includes FLT3 Inhibition Blood. 130: 2522-2522. DOI: 10.1182/Blood.V130.Suppl_1.2522.2522 |
0.467 |
|
| 2017 |
Kim W, Haws H, Peterson P, Whatcott CJ, Weitman S, Warner SL, Bearss DJ, Siddiqui-Jain A. Abstract 5133: TP-1287, an oral prodrug of the cyclin-dependent kinase-9 inhibitor alvocidib Cancer Research. 77: 5133-5133. DOI: 10.1158/1538-7445.Am2017-5133 |
0.406 |
|
| 2017 |
Livingston M, Kim W, Haws H, Peterson P, Whatcott CJ, Siddiqui-Jain A, Weitman S, Bearss DJ, Warner SL. Abstract 1106: Alvocidib potentiates the activity of venetoclax in preclinical models of multiple myeloma Cancer Research. 77: 1106-1106. DOI: 10.1158/1538-7445.Am2017-1106 |
0.493 |
|
| 2016 |
Jimenez L, Wang J, Morrison MA, Whatcott C, Soh KK, Warner S, Bearss D, Jette CA, Stewart RA. Phenotypic chemical screening using a zebrafish neural crest EMT reporter identifies retinoic acid as an inhibitor of epithelial morphogenesis. Development (Cambridge, England). 143: e1.1. PMID 27095497 DOI: 10.1242/Dev.138388 |
0.306 |
|
| 2016 |
Jimenez L, Wang J, Morrison MA, Whatcott C, Soh KK, Warner S, Bearss D, Jette CA, Stewart RA. Phenotypic chemical screening using zebrafish neural crest reporters identifies retinoid acid as an inhibitor of epithelial morphogenesis. Disease Models & Mechanisms. PMID 26794130 DOI: 10.1242/Dmm.021790 |
0.439 |
|
| 2016 |
Peterson P, Kim W, Haws H, Whatcott CJ, Siddiqui-Jain A, Bearss DJ, Warner SL. The ALK-2 Inhibitor, TP-0184, Demonstrates High Distribution to the Liver Contributing to Significant Preclinical Efficacy in Mouse Models of Anemia of Chronic Disease Blood. 128: 263-263. DOI: 10.1182/Blood.V128.22.263.263 |
0.418 |
|
| 2016 |
Sinha S, Boysen JC, Chaffee KG, Kabat BF, Slager SL, Parikh SA, Secreto CR, Shanafelt TD, Leis JF, Warner SL, Bearss DJ, Ghosh AK, Kay NE. Sensitivity of Ibrutinib Exposed Chronic Lymphocytic Leukemia B-Cells to Inhibition of Axl Receptor Tyrosine Kinase Blood. 128: 2020-2020. DOI: 10.1182/Blood.V128.22.2020.2020 |
0.438 |
|
| 2016 |
Whatcott CJ, Bogenberger JM, Kim W, Haws H, Hansen N, Delman D, Sproat L, Palmer J, Mesa RA, Peterson P, Siddiqui-Jain A, Weitman S, Bearss DJ, Warner SL, Tibes R. Alvocidib Potentiates the Activity of Venetoclax in Preclinical Models of Acute Myeloid Leukemia Blood. 128: 1652-1652. DOI: 10.1182/Blood.V128.22.1652.1652 |
0.467 |
|
| 2016 |
Jimenez L, Whatcott C, Wang J, Warner S, Morrison M, Bearss D, Stewart RA. Abstract IA29: Identifying epithelial morphogenesis inhibitors in neural crest development and cancer Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Devbiolca15-Ia29 |
0.496 |
|
| 2016 |
Kim W, Soh KK, Lee YS, Peterson P, Whatcott CJ, Siddiqui-Jain A, Weitman S, Bearss DJ, Warner SL. Abstract 3728: Targeting MCL-1 expression, through the inhibition of CDK9 and super enhancer driven transcription, offers multiple opportunities for rational drug combinations Cancer Research. 76: 3728-3728. DOI: 10.1158/1538-7445.Am2016-3728 |
0.536 |
|
| 2016 |
Soh KK, Kim W, Lee YS, Peterson P, Siddiqui-Jain A, Warner SL, Bearss DJ, Whatcott CJ. Abstract 235: AXL inhibition leads to a reversal of a mesenchymal phenotype sensitizing cancer cells to targeted agents and immuno-oncology therapies Cancer Research. 76: 235-235. DOI: 10.1158/1538-7445.Am2016-235 |
0.516 |
|
| 2015 |
Sinha S, Boysen J, Nelson M, Warner SL, Bearss D, Kay NE, Ghosh AK. Axl activates fibroblast growth factor receptor pathway to potentiate survival signals in B-cell chronic lymphocytic leukemia cells. Leukemia. PMID 26598018 DOI: 10.1038/Leu.2015.323 |
0.395 |
|
| 2015 |
Park IK, Mundy-Bosse B, Whitman SP, Zhang X, Warner SL, Bearss DJ, Blum W, Marcucci G, Caligiuri MA. Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia. Leukemia. PMID 26172401 DOI: 10.1038/leu.2015.147 |
0.4 |
|
| 2015 |
Sinha S, Boysen J, Nelson M, Secreto C, Warner SL, Bearss DJ, Lesnick C, Shanafelt TD, Kay NE, Ghosh AK. Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2115-26. PMID 25673699 DOI: 10.1158/1078-0432.Ccr-14-1892 |
0.519 |
|
| 2015 |
Kim W, Bahr BL, Soh KK, Bearss JJ, Lee YS, Peterson P, Whatcott CJ, Siddiqui-Jain A, Weitman S, Bearss DJ, Warner SL. Alvocidib Potentiates the Activity of Cytarabine and Mitoxantrone through the Targeting of MCL-1 When Administered in a Time Sequential Regimen in AML Blood. 126: 3799-3799. DOI: 10.1182/Blood.V126.23.3799.3799 |
0.478 |
|
| 2015 |
Soh KK, Bahr BL, Bearss JJ, Kim W, Peterson P, Whatcott CJ, Siddiqui-Jain A, Bearss DJ, Warner SL. Inhibition of Axl Kinase Reverses the Mesenchymal Phenotype in Leukemic Cells through the Disruption of Retinoic Acid Signaling Blood. 126: 3253-3253. DOI: 10.1182/Blood.V126.23.3253.3253 |
0.442 |
|
| 2015 |
Peterson P, Soh KK, Lee YS, Kim W, Whatcott CJ, Siddiqui-Jain A, Bearss DJ, Warner SL. ALK2 Inhibition Via TP-0184 Abrogates Inflammation-Induced Hepcidin Expression and Is a Potential Therapeutic for Anemia of Chronic Disease Blood. 126: 273-273. DOI: 10.1182/Blood.V126.23.273.273 |
0.412 |
|
| 2015 |
Kim W, Soh KK, Bearss JJ, Lee YS, Peterson P, Whatcott CJ, Siddiqui-Jain A, Weitman S, Bogenberger JM, Tibes R, Bearss DJ, Warner SL. Alvocidib Potentiates the Activity of Azacytidine in an MCL-1-Dependent Fashion Blood. 126: 1343-1343. DOI: 10.1182/Blood.V126.23.1343.1343 |
0.469 |
|
| 2015 |
Jimenez L, Wang J, Jette C, Warner SL, Bearss D, Stewart R. Abstract 4096: Identification of EMT inhibitors using novel zebrafish reporter lines Cancer Research. 75: 4096-4096. DOI: 10.1158/1538-7445.Am2015-4096 |
0.518 |
|
| 2015 |
Bearss JJ, Bahr BL, Soh KK, Peterson PW, Whatcott CJ, Siddiqui-Jain A, Bearss DJ, Warner SL. Abstract 3604: Targeting the PIM kinases in combination with BTK inhibition is synergistic in preclinical models of B-cell malignancies Cancer Research. 75: 3604-3604. DOI: 10.1158/1538-7445.Am2015-3604 |
0.587 |
|
| 2015 |
Balaji K, Cardnell R, Diao L, Tong P, Mak M, Fan YH, Masrorpour F, Warner SL, Bearss DJ, Wistuba I, Mills GB, Heymach J, Keyomarsi K, Wang J, Byers LA. Abstract 3579: Identification of biomarkers of AXL-mediated drug resistance in head and neck squamous cell carcinoma Cancer Research. 75: 3579-3579. DOI: 10.1158/1538-7445.Am2015-3579 |
0.518 |
|
| 2015 |
Dettman EJ, Warner SL, Doykan C, Arn M, Blake N, Bearss DJ, Cardone M, Smith BD. Abstract 3400: Mitochondrial profiling in AML patients treated with an Alvocidib containing regimen reveals MCL1 dependency in responder bone marrow Cancer Research. 75: 3400-3400. DOI: 10.1158/1538-7445.Am2015-3400 |
0.364 |
|
| 2015 |
Lee YS, Kim W, Soh KK, Peterson P, Whatcott CJ, Siddiqui-Jain A, Bearss DJ, Warner SL. Abstract C202: CDK9 inhibition synergizes with BRD4 inhibitor-mediated super enhancer transcriptional repression in multiple preclinical tumor models Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C202 |
0.526 |
|
| 2015 |
Kim W, Bahr BL, Soh KK, Bearss JJ, Lee YS, Peterson P, Whatcott CJ, Siddiqui-Jain A, Weitman S, Bearss DJ, Warner SL. The MCL-1 targeting effect of alvocidib potentiates the activity of cytarabine and mitoxantrone in a time-sequential regimen in AML Clinical Lymphoma, Myeloma & Leukemia. 15. DOI: 10.1016/J.Clml.2015.07.041 |
0.337 |
|
| 2014 |
Meng L, Carpenter K, Mollard A, Vankayalapati H, Warner SL, Sharma S, Tricot G, Zhan F, Bearss DJ. Inhibition of Nek2 by small molecules affects proteasome activity. Biomed Research International. 2014: 273180. PMID 25313354 DOI: 10.1155/2014/273180 |
0.535 |
|
| 2014 |
Warner SL, Carpenter KJ, Bearss DJ. Activators of PKM2 in cancer metabolism. Future Medicinal Chemistry. 6: 1167-78. PMID 25078136 DOI: 10.4155/Fmc.14.70 |
0.499 |
|
| 2014 |
Foulks JM, Carpenter KJ, Luo B, Xu Y, Senina A, Nix R, Chan A, Clifford A, Wilkes M, Vollmer D, Brenning B, Merx S, Lai S, McCullar MV, Ho KK, ... ... Warner SL, et al. A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas. Neoplasia (New York, N.Y.). 16: 403-12. PMID 24953177 DOI: 10.1016/J.Neo.2014.05.004 |
0.545 |
|
| 2014 |
Boysen J, Sinha S, Price-Troska T, Warner SL, Bearss DJ, Viswanatha D, Shanafelt TD, Kay NE, Ghosh AK. The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: implications for therapy in p53-defective CLL patients. Leukemia. 28: 451-5. PMID 24217154 DOI: 10.1038/Leu.2013.298 |
0.312 |
|
| 2014 |
Sinha S, Boysen J, Secreto C, Warner SL, Kay NE, Ghosh AK. Axl Regulates Fibroblast Growth Factor Receptor Signaling in B-Cell Chronic Lymphocytic Leukemia: Dual Targeting in CLL Therapy Blood. 124: 831-831. DOI: 10.1182/Blood.V124.21.831.831 |
0.493 |
|
| 2014 |
Park I, Mundy-Bosse B, Warner SL, Bearss DJ, Marcucci G, Caligiuri MA. The Receptor Tyrosine Kinase Axl Is Required for Resistance to FLT3-Targeted Therapy in Acute Myeloid Leukemia Blood. 124: 2350-2350. DOI: 10.1182/Blood.V124.21.2350.2350 |
0.496 |
|
| 2014 |
Kim W, Maughan KS, Soh KK, Bearss JJ, Bahr BL, Bearss DJ, Warner SL. Novel Series of ALK2 Inhibitors That Alter Hepcidin Expression As Potential Therapeutics for Anemia of Chronic Disease Blood. 124: 212-212. DOI: 10.1182/Blood.V124.21.212.212 |
0.435 |
|
| 2014 |
Sinha S, Boysen J, Nelson M, Secreto C, Warner SL, Bearss DJ, Lesnick C, Shanafelt TD, Kay NE, Ghosh AK. Targeted Inhibition of Axl Primes Chronic Lymphocytic Leukemia B-Cells for Apoptosis: Synergistic/Additive Effects in Combination with Bruton Tyrosine Kinase Inhibitors Blood. 124: 1946-1946. DOI: 10.1182/Blood.V124.21.1946.1946 |
0.508 |
|
| 2014 |
Pierceall WE, Warner SL, Lena RJ, Doykan C, Blake N, Elashoff M, Hoff DDV, Bearss DJ, Cardone MH, Grever M, Lanasa MC, Byrd JC, Johnson AJ. Abstract 907: Bcl-xL dependence predicts response to alvocidib in chronic lymphocytic leukemia patients Cancer Research. 74: 907-907. DOI: 10.1158/1538-7445.Am2014-907 |
0.324 |
|
| 2014 |
Sinha S, Boyson J, Secreto C, Warner SL, Kay NE, Ghosh AK. Abstract 3448: Fibroblast growth factor receptor is expressed as a constitutively active receptor tyrosine kinase in chronic lymphocytic leukemia B cells and exists in an active complex with Axl: Dual targeting in CLL Cancer Research. 74: 3448-3448. DOI: 10.1158/1538-7445.Am2014-3448 |
0.507 |
|
| 2013 |
Sorna V, Theisen ER, Stephens B, Warner SL, Bearss DJ, Vankayalapati H, Sharma S. High-throughput virtual screening identifies novel N'-(1-phenylethylidene)-benzohydrazides as potent, specific, and reversible LSD1 inhibitors. Journal of Medicinal Chemistry. 56: 9496-508. PMID 24237195 DOI: 10.1021/Jm400870H |
0.417 |
|
| 2013 |
Wang X, Saso H, Iwamoto T, Xia W, Gong Y, Pusztai L, Woodward WA, Reuben JM, Warner SL, Bearss DJ, Hortobagyi GN, Hung MC, Ueno NT. TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase. Cancer Research. 73: 6516-25. PMID 24014597 DOI: 10.1158/0008-5472.Can-13-0967 |
0.514 |
|
| 2013 |
Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, ... Warner SL, et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 279-90. PMID 23091115 DOI: 10.1158/1078-0432.Ccr-12-1558 |
0.415 |
|
| 2013 |
Cardnell R, Diao L, Wang J, Bearss D, Warner S, Fan YH, Giri U, Story MD, Weinstein JN, Coombes KR, Williams MD, Genome Atlas Reseach Network TC, Wistuba II, Mills GB, Myers J, et al. An epithelial-mesenchymal transition (EMT) gene signature to predict resistance to EGFR inhibition and AXL identification as a therapeutic target in head and neck squamous cell carcinoma. Journal of Clinical Oncology. 31: 6011-6011. DOI: 10.1200/Jco.2013.31.15_Suppl.6011 |
0.493 |
|
| 2013 |
Faris M, Malyankar UM, Tam V, Schweitzer C, Joea D, Mollard A, Stephens B, Warner SL, Bearss DJ, Zeng Q. Abstract LB-303: Small molecule inhibitor of the BTK pathway disrupts BCR signaling and demonstrates antitumor efficacy in a xenograft model. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-303 |
0.579 |
|
| 2013 |
Stephens BJ, Mollard A, Meng L, Bearss DJ, Warner SL. Abstract 904: TP-0413 is a dual-specific inhibitor against Jak2 and Alk2 with therapeutic potential for treating anemia of chronic disease. Cancer Research. 73: 904-904. DOI: 10.1158/1538-7445.Am2013-904 |
0.498 |
|
| 2013 |
Anderson M, Ober A, Mollard A, Call L, Bearss JJ, Vankayalapati H, Sharma S, Warner S, Bearss DJ. Abstract 5543: Inhibition of the tyrosine kinase receptor Axl blocks cell invasion and promotes apoptosis in pancreatic cancer cells. Cancer Research. 73: 5543-5543. DOI: 10.1158/1538-7445.Am2013-5543 |
0.567 |
|
| 2013 |
Walker B, Venkataswamy S, Warner S, Call L, Vankayalapati H, Sharma S, Bearss DJ. Abstract 4413: Mechanisms of sensitivity to treatment with the PDK1 inhibitors HCI-1680 and HCI-1708. Cancer Research. 73: 4413-4413. DOI: 10.1158/1538-7445.Am2013-4413 |
0.588 |
|
| 2013 |
Carpenter KJ, Brog R, Moreno C, Albertson DJ, Bearss JJ, Liu T, Warner S, Bearss DJ. Abstract 2174: Small molecule iInhibitors of PIM kinases as potential treatments for urothelial carcinomas. Cancer Research. 73: 2174-2174. DOI: 10.1158/1538-7445.Am2013-2174 |
0.497 |
|
| 2013 |
Bahr BL, Stevens J, Squire S, Moreno C, Call LT, Stephens BJ, Mollard A, Warner SL, Bearss DJ. Abstract 1875: A novel series of metabolic activators of PKM2 alter oncogene-meditated changes in tumor cell metabolism. Cancer Research. 73: 1875-1875. DOI: 10.1158/1538-7445.Am2013-1875 |
0.476 |
|
| 2011 |
Mollard A, Warner SL, Call LT, Wade ML, Bearss JJ, Verma A, Sharma S, Vankayalapati H, Bearss DJ. Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors. Acs Medicinal Chemistry Letters. 2: 907-912. PMID 22247788 DOI: 10.1021/Ml200198X |
0.502 |
|
| 2011 |
Verma A, Warner SL, Vankayalapati H, Bearss DJ, Sharma S. Targeting Axl and Mer kinases in cancer. Molecular Cancer Therapeutics. 10: 1763-73. PMID 21933973 DOI: 10.1158/1535-7163.Mct-11-0116 |
0.507 |
|
| 2011 |
Chung JY, Davis JA, Price BD, Staley DM, Wagner MV, Warner SL, Bearss DJ, Hansen MD. Competitive enhancement of HGF-induced epithelial scattering by accessory growth factors. Experimental Cell Research. 317: 307-18. PMID 21075102 DOI: 10.1016/j.yexcr.2010.11.002 |
0.301 |
|
| 2011 |
Ahmed KB, Warner SL, Chen A, Gourley ES, Liu X, Vankayalapati H, Nussenzveig R, Prchal JT, Bearss DJ, Parker CJ. In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2. Experimental Hematology. 39: 14-25. PMID 20934482 DOI: 10.1016/J.Exphem.2010.09.013 |
0.548 |
|
| 2011 |
Stephens BJ, Warner SL, Vankayalapati H, Bearss DJ, Sharma S. Abstract LB-187: Identification of CIT-0665, a novel inhibitor of LSD1 Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-187 |
0.493 |
|
| 2011 |
Bearss DJ, Venkataswamy S, Warner SL, Vankayalapati H, Bearss JJ, Sharma S. Abstract 2788: Design, optimization, and biological evaluation of potent irreversible inhibitors of BTK kinase Cancer Research. 71: 2788-2788. DOI: 10.1158/1538-7445.Am2011-2788 |
0.388 |
|
| 2010 |
Chuang JC, Warner SL, Vollmer D, Vankayalapati H, Redkar S, Bearss DJ, Qiu X, Yoo CB, Jones PA. S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Molecular Cancer Therapeutics. 9: 1443-50. PMID 20442312 DOI: 10.1158/1535-7163.Mct-09-1048 |
0.309 |
|
| 2009 |
Warner SL, Stephens BJ, Nwokenkwo S, Hostetter G, Sugeng A, Hidalgo M, Trent JM, Han H, Von Hoff DD. Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 6519-28. PMID 19861455 DOI: 10.1158/1078-0432.Ccr-09-0077 |
0.419 |
|
| 2009 |
Gourley ES, Liu X, Hewitt W, Walker R, Warner SL, Vankayalapati H, Bearss DJ. Targeting Axl Kinase in Hematological Malignancies. Blood. 114: 2758-2758. DOI: 10.1182/Blood.V114.22.2758.2758 |
0.581 |
|
| 2009 |
David V, Bearss J, Jones C, McCarthy V, Gourley E, Liu X, Vankayalapati H, Warner S, Olsen C, Bearss D. Abstract C206: In vivo activity of SGI‐1252, a potent, small‐molecule dual inhibitor of JAK2 and ALK2 Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-C206 |
0.452 |
|
| 2009 |
Vollmer D, Bearss J, Jones C, McCarthy V, Shi C, Tang C, Gourley E, Liu X, Hewitt W, Vankayalapati H, Warner S, Olsen C, Bearss D. Abstract C199: Development of potent, small‐molecule inhibitors of ETK Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-C199 |
0.502 |
|
| 2009 |
Gourley ES, Liu X, Hewitt W, Walker R, Warner SL, Vankayalapati H, Bearss DJ. Abstract B263: Mechanistic, functional, and in vivo efficacy of inhibiting ETK/BMX in cancer models Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-B263 |
0.551 |
|
| 2008 |
Warner SL, Muñoz RM, Bearss DJ, Grippo P, Han H, Von Hoff DD. Pdx-1-driven overexpression of aurora a kinase induces mild ductal dysplasia of pancreatic ducts near islets in transgenic mice. Pancreas. 37: e39-44. PMID 18815537 DOI: 10.1097/Mpa.0B013E318176B9Ae |
0.392 |
|
| 2008 |
Warner SL, Stephens BJ, Von Hoff DD. Tubulin-associated proteins: Aurora and Polo-like kinases as therapeutic targets in cancer. Current Oncology Reports. 10: 122-9. PMID 18377825 DOI: 10.1007/S11912-008-0020-0 |
0.488 |
|
| 2008 |
Ahmed KBR, Nussenzveig RH, Chen AT, Prchal JT, Parker CJ, Gourley E, Severson P, Bearss J, Jones C, Warner SL, Vollmer D, Bearss DJ. Preclinical Characterization of the JAK-2 Inhibitor, SGI-1252 Blood. 112: 2629-2629. DOI: 10.1182/Blood.V112.11.2629.2629 |
0.466 |
|
| 2008 |
Bearss D, Gourley E, Liu XH, Bearss J, Jones C, Olsen C, Vollmer D, Warner S, Vankayalapati H, Severson P. 332 POSTER In vivo activity of SGI-1776, an orally active Pim kinase inhibitor Ejc Supplements. 6: 105-106. DOI: 10.1016/S1359-6349(08)72266-3 |
0.438 |
|
| 2007 |
Olsen CE, Gourley ES, Lui X, Walker J, Grand CL, Warner SL, Vankayalapati H, Bearss DJ. Targeting the JAK2 Kinase in Hematological Malignancies. Blood. 110: 3560-3560. DOI: 10.1182/Blood.V110.11.3560.3560 |
0.752 |
|
| 2006 |
Warner SL, Munoz RM, Stafford P, Koller E, Hurley LH, Von Hoff DD, Han H. Comparing Aurora A and Aurora B as molecular targets for growth inhibition of pancreatic cancer cells. Molecular Cancer Therapeutics. 5: 2450-8. PMID 17041088 DOI: 10.1158/1535-7163.Mct-06-0202 |
0.607 |
|
| 2006 |
Warner SL, Bashyam S, Vankayalapati H, Bearss DJ, Han H, Mahadevan D, Von Hoff DD, Hurley LH. Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach. Molecular Cancer Therapeutics. 5: 1764-73. PMID 16891462 DOI: 10.1158/1535-7163.Mct-05-0524 |
0.627 |
|
| 2006 |
Warner SL, Gray PJ, Von Hoff DD. Tubulin-associated drug targets: Aurora kinases, Polo-like kinases, and others. Seminars in Oncology. 33: 436-48. PMID 16890798 DOI: 10.1053/J.Seminoncol.2006.04.007 |
0.494 |
|
| 2003 |
Warner SL, Bearss DJ, Han H, Von Hoff DD. Targeting Aurora-2 kinase in cancer. Molecular Cancer Therapeutics. 2: 589-95. PMID 12813139 |
0.383 |
|
| Show low-probability matches. |